Osimertinib is a potent, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) selective for EGFR-TKI sensitizing (EGFRm) and T790M resistance mutations. The primary objective of the cytology cohort in the AURA study was to investigate safety and efficacy of osimertinib in pretreated Japanese patients with EGFR T790M mutation-positive non-small cell lung cancer (NSCLC), with screening EGFR T790M mutation status determined from cytology samples.
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| INTRODUCTION
Epidermal growth factor receptor-TKI, such as erlotinib, afatinib and gefitinib, are recommended as first-line therapy and have shown clinical benefit in patients with advanced NSCLC harboring an EGFRm. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] However, the majority of patients who initially respond to EGFR-TKI ultimately develop acquired resistance; approximately 60% of such patients harbor the EGFR T790M resistance mutation. 11, 12 Osimertinib is an oral, potent, irreversible EGFR-TKI selective for both EGFRm and T790M resistance mutations. 13 Following positive outcomes from the AURA clinical programme (AURA Phase I with Phase II extension NCT01802632, AURA2 Phase II study NCT02094261, and AURA3 Phase III study NCT02151981), [14] [15] [16] [17] osimertinib is recommended as a treatment choice for patients with EGFR T790M-positive advanced NSCLC following disease progression on first-line EGFR-TKI. 18 The Phase I part of the AURA study comprised dose escalation and dose expansion components. The dose expansion component enrolled patients based on confirmation of tumor EGFRm status from a biopsy sample. A cytology cohort was included as part of the dose expansion component at the osimertinib 80-mg once-daily dose and enrolled patients based on EGFR T790M mutation status derived from a cytology sample. The Phase II and III studies (AURA extension, AURA2 and AURA3) enrolled patients based upon central T790M mutation testing of a tumor biopsy sample following confirmed disease progression on a prior EGFR-TKI.
Generally, patients who do not have solid tumor deposits suitable for tumor biopsy are excluded from clinical studies or access to licensed medicines that require prospective companion diagnostic testing. Cytology sampling may provide sufficient tumor material for molecular analysis and is a less invasive approach to tumor characterization than solid tumor biopsy. Studies have shown cytological samples to have equivalent or higher sensitivity and accuracy for identifying EGFR mutations in NSCLC when compared with surgical specimens. 19, 20 Furthermore, cytological samples taken directly from tumors may provide higher sensitivity for EGFR mutations than plasma-based testing as a result of higher tumor DNA load. In a recent analysis of plasma vs tumor tissue for the detection of EGFR T790M in patients with EGFRm advanced NSCLC and disease progression on a first-line EGFR-TKI, sensitivity (positive percent agreement) was 51%. 21 However, plasma-based testing is less invasive than cytological-based testing.
In Japan, almost 40% of EGFR mutation testing is undertaken using cytological samples; Japanese clinicians treating NSCLC consider cytological samples to be valuable clinical specimens for testing EGFR mutations as they are collected less invasively than tissue samples. 22 Therefore, the cytology cohort was planned to include Japanese patients only.
Assays available for cytology-based EGFR testing include PCR- 
| MATERIALS AND METHODS

| Study design and participants
The AURA study was a Phase I/II, open-label, multicenter study of osimertinib given orally in patients with advanced NSCLC and disease progression following prior therapy with an EGFR-TKI. The primary objective of the study was to determine the safety and efficacy of osimertinib. The Phase I component of the study consisted of dose escalation and dose expansion components and has been published previously. Informed consent was obtained from all patients prior to initiation of the study.
| Procedures
Eligible patients received an osimertinib 80-mg tablet once daily until RECIST version 1.1-defined disease progression or until clinical benefit was no longer observed, as judged by the investigator.
All patients in the cohort were recruited based on confirmation of EGFR T790M mutation-positive status through molecular analysis of a cytological sample, conducted with an acceptable method per institution guidance. Cytological samples were collected using a variety of methods, including by BAL, thoracocentesis, fine-needle aspiration, bronchial brushing, or other methods (trans-bronchial lung biopsy, washings of biopsy device or lumbar puncture) and EGFR T790M-positive status was determined by local laboratory testing using various technology platforms. An overview of the cytological sampling and EGFR T790M testing methods used is shown in Table 1 . If available, optional tissue and/or rest of the collected cytological samples were requested for provision for central testing by
Efficacy was primarily measured through ORR, defined by investigator assessment of radiological information using RECIST version 1.1. Additional efficacy endpoints included DoR, PFS, best F I G U R E 1 AURA Phase I study design, highlighting the Japanese expansion cohort
percentage change from baseline in TL size and DCR. Analysis of overall survival was not planned for the AURA study Phase I component. The safety and tolerability profile was assessed throughout the study using AE graded according to the NCI CTCAE version 4, as well as through clinical chemistry, hematology, urinalysis, vital signs, electrocardiograms and physical examinations. PK data were investigated as a secondary outcome measure by venous blood samples and standard non-compartmental analysis of plasma concentration data for osimertinib and its metabolites. Details of PK analysis are included as Doc. S1.
| Statistical analysis
Thirty patients were planned for inclusion in the evaluable-forresponse set to provide an estimate of the true response rate for the population. The evaluable-for-response data set and safety analysis included all patients who received at least one dose of osimertinib and had measureable disease at baseline. The PK analysis included all dosed patients who had at least one measurable plasma concentration collected after dosing.
ORR, BOR, DoR, DCR and maximum tumor shrinkage were con- 3 | RESULTS
| Demographics
Overall, 28 patients from 13 institutions were enrolled into this cohort. Baseline characteristics are summarized in Table 2 . The majority of patients were female (75%), with adenocarcinoma histology (86%), a World Health Organization (WHO) performance status score of 1 (75%) and had never smoked (64%). All patients were of Japanese ethnicity. 
| Duration of treatment
| Cytology
Cytology samples were collected from BAL (n = 12), thoracocentesis (n = 6), fine-needle aspiration (n = 5), bronchial brushing (n = 2) or other (n = 3). T790M testing was by PNA-LNA PCR clamp (n = 16), Scorpion-ARMS (n = 7) or Cycleave (n = 5). An overview of the methods used is shown in Table 1 with details of patient characteristics by cytological sampling and T790M testing methods included as ARMS, Amplification Refractory Mutation System; PNA-LNA, peptide nucleic acid-locked nucleic acid.
Other includes trans-bronchial lung biopsy (n = 1), washings of biopsy device (n = 1), lumbar puncture (n = 1).
baseline at 6 weeks of À39% (SD 21.5) (Figure 2 ). DCR was 96% (95% CI 82, 100). Median DoR was 9.7 months (95% CI 3.8, NC). A summary of individual patient DoR is shown in Figure 3 and a DoR
Kaplan-Meier curve is included as Figure S1 . Response rate at 6 months was 62% (95% CI 38, 79), 52% (95% CI 29, 70) at 9 months and 41% (95% CI 20, 61) at 12 months.
| Progression-free survival
There were a total of 17 progression events (61%). Median PFS was 
| Safety
All 28 patients (100%) reported at least one AE, with 27 patients (96%) reporting a possibly causally related AE (as assessed by the investigator). A description of AE reported in ≥15% of patients is shown in Table 3 . The most common all-causality AE were dermatological or gastrointestinal in nature: paronychia (46%), dry skin (46%), diarrhea (36%) and rash (36%). ILD-like AE were reported in 5 patients (18%), with three (11%) cases of pneumonitis and two (7%) of ILD. There were five QT prolongation events, four classified as CTCAE grade 1 and one classified as CTCAE grade 2.
Overall, 16 (57%) patients experienced an AE of Grade 3 or higher, most commonly neutrophil count decrease (3 patients [11%]), followed by pneumonitis and white blood cell count decrease (each reported in 2 patients [7%]). SAE were reported in 4 patients (14%) ( Table 3) , three of which were considered to be related to the study drug; these were two reported cases of pneumonitis and one of ILD.
AE leading to dose reduction occurred in 6 patients (21%) and AE leading to dose interruption occurred in 9 patients (32%) ( Table 3) .
AE leading to dose discontinuation occurred in 5 patients (18%); these were three reported cases of pneumonitis and two of ILD (all five were considered by the investigator as possibly related to osimertinib treatment). No deaths were reported in this cohort.
T A B L E 2 Baseline demographic and clinical characteristics
Characteristic, n (%) N = 28 
| DISCUSSION
Osimertinib is recommended as a treatment choice for patients with EGFR T790M-positive advanced NSCLC following progression on first-line EGFR-TKI. [25] [26] [27] Data from the current cytology cohort of the AURA study suggest that osimertinib 80 mg orally once daily provides clinical benefit with a manageable safety profile in Japanese patients with pretreated EGFR T790M mutation-positive NSCLC whose screening EGFR T790M mutation status was determined from cytology samples.
Although there have been advances in the early detection of NSCLC, the majority (80%-85%) of advanced-stage patients have unresectable disease. 28 In addition, the remaining 15%-20% of patients with resectable disease are often not appropriate for surgical resection as a result of significant comorbidities. 28 In these nonsurgical situations, cytological materials may be the only diagnostic specimens available. 28 Furthermore, patients who do not have solid tumor deposits suitable for biopsy are generally excluded from clinical studies or access to licensed medicines that require prospective testing. A cytology sample may offer sufficient material for molecular analysis and characterization of a tumor by a less invasive approach.
Comparative studies of cytology specimens and FFPE tissue in the analysis of genetic mutations in patients with cancer reported a high concordance rate between the samples and concluded cytological preparations to be a reliable source for molecular oncology testing. [29] [30] [31] This highlights the importance of investigating cytological samples for diagnostic and molecular characterization purposes. The current cohort in the Phase I expansion component of the AURA study was included to explore the efficacy, safety and tolerability of osimertinib in patients enrolled using a cytology sample for detection of the EGFR T790M mutation.
The most common method of cytological sampling used in this cohort was BAL, used in 12 patients (43% This category represents a grouped term for the event.
and median PFS 8.3 months, which were comparable to the results from AURA Phase II extension, AURA2 and AURA3 studies. [15] [16] [17] The PK results observed in Japanese patients enrolled into a cytology expansion cohort of the AURA study were shown to be broadly comparable with those reported in the rest of the global AURA Phase I study. 14, 33 Likewise, the safety and tolerability observed in this study are consistent with those reported in previous trials of osimertinib in pretreated patients with EGFR T790M mutation-positive advanced NSCLC. [14] [15] [16] [17] 34 The frequency of ILD in this study was higher than that previously reported in Japanese patients with EGFR 
